The hospital and specialty pharmacy channel is the commercial backbone of the modern pharmaceutical industry’s highest-value products. Specialty pharmacy has grown to represent the majority of pharmaceutical revenue growth in the U.S., driven by the concentration of new product launches in oncology, rare disease, immunology, and neuroscience. CAR-T therapy has created the most complex pharmaceutical commercial channel in history — requiring coordination between hospital treatment center, manufacturing facility, leukapheresis collection site, cold-chain transportation, and a complex reimbursement process. The three largest specialty pharmacy operators — CVS Specialty, Accredo, and Optum Specialty — collectively manage drug distribution for the majority of high-cost biologic therapies in the U.S.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Specialty Pharmacy Structure
• Oncology Infusion Centers
• CAR-T Commercial Infrastructure
• Rare Disease Commercial Model
• Hospital Formulary and P&T Committees
• 340B Drug Pricing Program
Table of Contents
1. Executive Summary
2. Market Overview
3. Specialty Pharmacy Structure
4. Oncology Infusion Centers
5. CAR-T Commercial Infrastructure
6. Rare Disease Commercial Model
7. Hospital Formulary and P&T Committees
8. 340B Drug Pricing Program
9. Competitive Landscape
10. Regional Market Analysis
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Market Overview 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Portfolio and Strategy Assessment 2025
Table 3. M&A and Partnership Activity 2023-2025
Table 4. Regional Analysis
Table 5. Key Risks and Mitigation Strategies
Companies Profiled
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Pfizer
Novartis
Johnson & Johnson
Daiichi Sankyo
Seagen
AbbVie
